{"product_id":"afp-peptide-fmnkfiyei","title":"AFP Peptide (FMNKFIYEI)","description":"\u003cdiv style=\"max-width:1400px; margin:0 auto; padding:40px 20px; font-family:'Open Sans',sans-serif; font-weight:300; background:#fff; color:#333; font-size:0.95rem; box-sizing:border-box;\"\u003e\n  \u003cdiv style=\"display:flex; flex-direction:column; gap:20px;\"\u003e\n\u003ch2 style=\"margin:0; font-weight:600;\"\u003eAFP Peptide (FMNKFIYEI) – Catalog #B2026709\u003c\/h2\u003e\n\u003cp\u003eAFP Peptide FMNKFIYEI (Catalog #B2026709) is a synthetic 9-amino-acid peptide (Phe–Met–Asn–Lys–Phe–Ile–Tyr–Glu–Ile) derived from alpha-fetoprotein, a 70 kDa glycoprotein produced by the fetal liver and yolk sac during early development. In adults, AFP is a marker of hepatocellular carcinoma, hepatoblastoma, and certain germ cell tumors. The FMNKFIYEI sequence represents an immunogenic epitope recognized by helper T cells and used in cancer vaccine research to elicit or enhance anti-AFP immune responses. Supplied as 1 mg of lyophilized powder (MW 1204.45 Da), this peptide is suitable for immunization protocols, antibody generation, epitope mapping, and immunological assays.\u003c\/p\u003e\n\u003cdiv style=\"overflow-x:auto; max-width:100%; margin-bottom:20px;\"\u003e\n\u003ctable style=\"width:100%; max-width:640px; border-collapse:collapse;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eCatalog number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eB2026709\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eLot number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eExpiration Date:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eAmount:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e1 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003ePeptide sequence:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eFMNKFIYEI\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e1204.45 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eAmino acid composition:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eF (2), M (1), N (1), K (1), I (2), Y (1), E (1)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSupplied as:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eApplications:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eImmunization, antibody generation, cancer vaccine development, epitope mapping, CD4 T cell recognition studies, flow cytometry, ELISA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e-20°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eAFP peptide, alpha-fetoprotein peptide, FMNKFIYEI, AFP epitope, cancer immunotherapy, HCC epitope, immunogenic peptide, synthetic peptide\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eGrade:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBiotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity \u0026gt;18 MΩ-cm) and are filtered through 0.22 μm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eScientific Overview\u003c\/h3\u003e\n\u003cp\u003eAlpha-fetoprotein (AFP) is a 70 kDa glycoprotein synthesized during fetal development by the yolk sac and fetal liver. After birth, AFP production drops sharply; in adults, elevated serum AFP is associated with hepatocellular carcinoma (HCC), hepatoblastoma, and non-seminomatous germ cell tumors, making it a clinically important tumor marker. Beyond its diagnostic value, AFP is a target for cancer immunotherapy: T cell-based and peptide-based vaccines have been developed to elicit AFP-specific immune responses and reduce HCC recurrence.\u003c\/p\u003e\n\u003cp\u003eThe FMNKFIYEI sequence is an identified helper T cell epitope (MHC class II-restricted) derived from AFP. This peptide, and related AFP-derived epitope peptides, have been used in preclinical and clinical studies to induce anti-AFP immune responses, either alone or combined with other tumor antigens or immunostimulatory molecules (e.g., heat shock proteins, adjuvants, or immune-checkpoint inhibitors). The peptide's immunogenicity may vary depending on the MHC haplotype of the immunized host.\u003c\/p\u003e\n\u003cp\u003eKey applications include:\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003ePeptide-based cancer vaccine research for hepatocellular carcinoma\u003c\/li\u003e\n\u003cli\u003eInduction of CD4+ helper T cell responses against AFP\u003c\/li\u003e\n\u003cli\u003eEpitope mapping and immunogenic site identification\u003c\/li\u003e\n\u003cli\u003eGeneration of AFP-specific antibodies or T cell receptors\u003c\/li\u003e\n\u003cli\u003eStudy of AFP-specific immune tolerance and anti-tumor immunity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eUsage \u0026amp; Handling Guidance\u003c\/h3\u003e\n\u003cp\u003eStore at -20°C, protected from moisture. Reconstitute the lyophilized powder in sterile water or appropriate buffer immediately before use.\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Dissolve in sterile water, PBS, or assay buffer. For immunization, peptide concentration should be optimized based on your immunization schedule and adjuvant choice.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunization protocol:\u003c\/strong\u003e Typically, peptide is co-administered with an adjuvant (e.g., Freund's adjuvant, alum, or modern adjuvants) to enhance immunogenicity. Consult published vaccination protocols for dosing guidance.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStability:\u003c\/strong\u003e Lyophilized peptide is stable long-term at -20°C. In solution, stability depends on buffer and storage conditions; aliquot and store at -20°C to minimize freeze-thaw cycles.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhat You Get\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e1 mg of FMNKFIYEI peptide (MW 1204.45 Da), supplied as lyophilized powder\u003c\/li\u003e\n\u003cli\u003eA defined, immunogenic AFP epitope for cancer vaccine research\u003c\/li\u003e\n\u003cli\u003eHigh purity suitable for immunological and immunochemical applications\u003c\/li\u003e\n\u003cli\u003eFor research use only (RUO)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhy Researchers Choose It\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eDefined helper T cell epitope with documented immunogenicity\u003c\/li\u003e\n\u003cli\u003eSuitable for peptide-based vaccine development against HCC\u003c\/li\u003e\n\u003cli\u003eComplements antibody-based AFP detection in dual diagnostic\/therapeutic strategies\u003c\/li\u003e\n\u003cli\u003eCharacterized sequence enables reproducible immunological studies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eFrequently Asked Questions (FAQ)\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eIs this peptide immunogenic on its own?\u003c\/strong\u003e\u003cbr\u003eAFP peptides are generally poorly immunogenic without an adjuvant. Co-administer with Freund's, alum, or modern adjuvants; follow published cancer vaccine protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat is the best immunization route?\u003c\/strong\u003e\u003cbr\u003eSubcutaneous, intradermal, or intramuscular routes are typical. Consult the literature on AFP vaccines for dosing and schedule recommendations for your experimental model.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan I use this peptide to generate antibodies?\u003c\/strong\u003e\u003cbr\u003eYes. Conjugate this peptide to a carrier protein (e.g., KLH or BSA) before immunization to enhance antibody responses against the free peptide.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIs this peptide specific to one MHC allele?\u003c\/strong\u003e\u003cbr\u003eThe FMNKFIYEI epitope's presentation depends on MHC haplotype. Check published literature on MHC binding and T cell recognition for this sequence.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan I get documentation of purity or synthesis?\u003c\/strong\u003e\u003cbr\u003eYes. Request a quote or contact us and we will provide available lot documentation including mass spectrometry or HPLC purity data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin-top:20px; font-weight:bold; color:#c8102e;\"\u003eThis product is for Research Use Only (RUO). It is not intended for diagnostic or therapeutic use in humans or animals.\u003c\/div\u003e\n\u003chr\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003cul style=\"padding-left:0; margin:0; list-style:none;\"\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eHong Y, Peng Y, Guo ZS, Guevara-Patino J, Pang J, Butterfield LH, Mivechi NF, Munn DH, Bartlett DL, He Y. Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. \u003cem\u003eHepatology.\u003c\/em\u003e 2014;59(4):1448-58.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1002\/hep.26893\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eTamai T, Mizukoshi E, Kumagai M, Terashima T, Iida N, Kitahara M, Shimakami T, Kitamura K, Arai K, Yamashita T, Sakai Y, Yamashita T, Honda M, Fushimi K, Kaneko S. A novel α-fetoprotein-derived helper T-lymphocyte epitope with strong immunogenicity in patients with hepatocellular carcinoma. \u003cem\u003eSci Rep.\u003c\/em\u003e 2020;10(1):4021.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1038\/s41598-020-60843-4\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eWang XP, Wang QX, Lin HP, Xu B, Zhao Q, Chen K. Recombinant heat shock protein 70 functional peptide and alpha-fetoprotein epitope peptide vaccine elicits specific anti-tumor immunity. \u003cem\u003eOncotarget.\u003c\/em\u003e 2016;7(44):71274-71284.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.18632\/oncotarget.12464\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"Molecular Depot","offers":[{"title":"Default Title","offer_id":52805761990954,"sku":"BTS-B2026709","price":585.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/B2026709.png?v=1790801856","url":"https:\/\/bluetigerscientific.com\/products\/afp-peptide-fmnkfiyei","provider":"Blue Tiger Scientific","version":"1.0","type":"link"}